Skip to content

Dionyssios Sgouras

  • Director of Research, Medical Microbiology
  • Hellenic Pasteur Institute
  • 20h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 1564CitationsNumber of citations received by Dionyssios's publications. Updated daily.


Dr. Dionyssios Sgouras is currently a Principal Investigator at the Laboratory of Medical Microbiology of the Hellenic Pasteur Institute. Present research interests focus on bacterial pathogenesis and most specifically, Helicobacter pylori virulence factors and their effect on host intracellular signaling pathways, focusing mainly on epithelial cell pathogenesis and tissue remodeling during the infection. To this end, he was involved in FP5 program PROPATH CT-2000-01179 “Molecular Analysis and Mechanistic Elucidation of the Functionality of Probiotics and Prebiotics in the Inhibition of Pathogenic Microorganisms to Combat Gastrointestinal Disorders and to Improve Human Health” and the FP6 program ANR-06-PATHO-00701 project ERA-NET “Parasite and host genetic diversity in Helicobacter infections”. He is National Representative for the FP7 INFRA-2010-2.2.8 project ERINHA “European Research Infrastructure on Highly Pathogenic Agents” involving the construction and implementation of a pan-European high security BSL-4 research infrastructure for research on risk group 4 pathogens. Since May 2014 he has been appointed as the Head of Vaccines Unit at Hellenic Pasteur Institute. He is involved in the development of methods for the detection and typing of bacterial, parasitic and viral infectious agents in human as well as veterinary samples, to support the Diagnostic Department and the WHO-accredited National Reference Laboratories of the Hellenic Pasteur Institute. His experience in molecular methods include conventional- and nested- PCR, Real-Time PCR (Taqman and FRET methodology), isothermic RNA amplification (NASBA), b-DNA technology and transcription-mediated amplification (TMA). More specifically, he has extended experience in optimization and validation (sensitivity, specificity, positive- and negative-prognostic value, limit-of-detection etc.) of in-house molecular methods. He received his B.Sc. (Chemistry) from the National & Kapodistrian University of Athens in 1985. In 1987 he completed successfully a M.Sc. (by research) at the Department of Postgraduate Medicine of the University of Keele, UK. He completed his Ph.D. studies at the Cancer Research Campaign’s Polymer-Controlled Drug Delivery Research Group (CRC-PCDDRG), University of Keele, UK, on the biological characterization of soluble synthetic polymers to be used as carriers for controlled drug delivery of anticancer anthracycline antibiotics. Throughout 1991 he served as a Postdoctoral Research Fellow at the same laboratory working on the development of anticancer drug formulations for first order targeting to the lung, a project supported by Farmitalia Carlo Erba (Italy). From 1992 until 1995 having been awarded a U.S. National Institutes of Health-Fogarty International Fellowship he served as a postdoctoral research fellow at the Laboratory of Molecular Oncology, National Cancer Institute of the National Institutes of Health, based at the Frederick Cancer Research and Development Center in Frederick, MD. His work focused on the isolation and molecular characterization of ERF, a transcription factor of the ETS family of human oncogenes. During conscription, he served in the Greek Airforce (1996-1997) at the 251th Airforce Hospital, working in the Department of Nuclear Medicine and the Biochemistry Department. From 1997 until 2002, he was employed as a senior staff scientist at the Diagnostic Genetic Center S.A., a private laboratory involved in cytogenetic, biochemical and molecular prenatal screening. From 1999 until 2002 he worked as a Postdoctoral Research Fellow at the Hellenic Pasteur Institute, in the Laboratory of Medical Microbiology, in May 2002 he became Assistant Researcher and in 2010 promoted to Principal Investigator. He has over 30 publications in peer reviewed international journals and several publications in Greek journals. He holds 2 patents (US 6194547 and US 5856125), has authored one chapter in a book and has given over 20 invited talks in international conferences.

Recent publications

  • Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: A prospective open-label trial

    • Georgopoulos S
    • Papastergiou V
    • Martinez-Gonzalez B
    • et al.
  • Helicobacter pylori Adapts to Chronic Infection and Gastric Disease via pH-Responsive BabA-Mediated Adherence

    • Bugaytsova J
    • Björnham O
    • Chernov Y
    • et al.

Professional experience

Director of Research, Medical Microbiology

Hellenic Pasteur Institute

January 2018 - Present

Principal Investigator

Hellenic Pasteur Institute

April 2010 - December 2017(8 years)

Assistant Researcher

Hellenic Pasteur Institute

April 2002 - April 2010(8 years)

Staff Biochemist

Diagnostic Genetic Center, S.A.

November 1996 - April 2002(5 years)

Fogarty International Post-doctoral Fellow

Laboratory of Molecular Oncology, National Cancer Institute, Frederic Cancer Research and Development Center, National Cancer Institute, National Institutes of Health, USA

April 1992 - April 1995(3 years)

Post-doctoral fellow

Keele University, Polymer-Controlled Drug Delivery Research Group

January 1991 - January 1992(a year)



Keele University

September 1987 - July 1990(3 years)

MSc (by research)

Keele University

January 1986 - July 1987(2 years)

Bachelor's Degree in Chemistry

National and Kapodistrian University of Athens - National & Kapodistrian University of Athens

September 1981 - October 1985(4 years)

Co-authors (223)

Other IDs